Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TLSA
TLSA logo

TLSA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Tiziana Life Sciences Ltd (TLSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.250
1 Day change
1.22%
52 Week Range
2.600
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Tiziana Life Sciences Ltd (TLSA) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks significant positive catalysts, has neutral insider and hedge fund trading trends, and no recent AI Stock Picker or SwingMax signals. Additionally, the technical indicators show mixed signals with bearish moving averages and a neutral RSI. While the pre-market price is up 2.99%, this alone does not justify a long-term investment decision.

Technical Analysis

The MACD histogram is positive and expanding, which is a bullish signal. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. RSI is neutral at 65.539, and the stock is trading near its resistance level of 1.382, suggesting limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
0

Positive Catalysts

  • The MACD is positive and expanding, indicating some bullish momentum. Pre-market price is up 2.99%.

Neutral/Negative Catalysts

  • Bearish moving averages indicate a downward trend. Lack of significant trading trends from insiders or hedge funds. No recent news or event-driven catalysts. No AI Stock Picker or SwingMax signals.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast TLSA stock price to rise
Analyst Rating
0
Wall Street analysts forecast TLSA stock price to rise
Buy
Hold
Sell
0
Current: 1.230
sliders
Low
0
Averages
0
High
0
0
Current: 1.230
sliders
Low
0
Averages
0
High
0
Northland
Outperform
initiated
$12.50
AI Analysis
2026-01-08
Reason
Northland
Price Target
$12.50
AI Analysis
2026-01-08
initiated
Outperform
Reason
Northland named TriSalus Life Sciences as the analyst's Top Pick for 2026 with an Outperform rating and $12.50 price target on the shares. The firm see TriSalus' TriNav franchise emerging as a best-in-class platform for embolization procedures and expects continued market share gains in TACE and TARE procedures in the near-term, the analyst tells investors.
Lucid Capital
initiated
$8
2025-07-22
Reason
Lucid Capital
Price Target
$8
2025-07-22
initiated
Reason
Lucid Capital initiated coverage of Tiziana Life Sciences with a Buy rating and $8 price target. Tiziana is developing an intranasal antibody for numerous central nervous system conditions, the analyst tells investors in a research note. The firm believes the company is building a neurological franchise with foralumab that could be analogous to AbbVie's Humira.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TLSA
Unlock Now

People Also Watch